Risitano, A. M. et al. Complement as a target in COVID-19? Nat. Rev. Immunol. 20, 343–344 (2020).

CAS  PubMed  Article  Google Scholar 

Skendros, P. et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J. Clin. Invest. 130, 6151–6157 (2020).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Afzali, B. et al. The state of complement in COVID-19. Nat. Rev. Immunol. 22, 77–84 (2022).

CAS  PubMed  Article  Google Scholar 

Ramlall, V. et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat. Med. 26, 1609–1615 (2020).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Wang, E. Y. et al. Diverse functional autoantibodies in patients with COVID-19. Nature 595, 283–288 (2021).

CAS  PubMed  Article  Google Scholar 

Lopez, J. et al. Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs. J. Exp. Med. 218, e20211211 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Bastard, P. et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci. Immunol. 6, eabl4340 (2021).

PubMed  PubMed Central  Article  Google Scholar 

Troya, J. et al. Neutralizing autoantibodies to type I IFNs in >10% of patients with severe COVID-19 pneumonia hospitalized in Madrid, Spain. J. Clin. Immunol. 41, 914–922 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Bastard, P. et al. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J. Exp. Med. 218, e20210554 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Koning, R. et al. Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients. Intensive Care Med. 47, 704–706 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

de Prost, N. et al. Plasma exchange to rescue patients with autoantibodies against type I interferons and life-threatening COVID-19 pneumonia. J. Clin. Immunol. 41, 536–544 (2021).

PubMed  PubMed Central  Article  CAS  Google Scholar 

Bastard, P. et al. Interferon-β therapy in a patient with incontinentia pigmenti and autoantibodies against Type I IFNs Infected with SARS-CoV-2. J. Clin. Immunol. 41, 931–933 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Pairo-Castineira, E. et al. Genetic mechanisms of critical illness in COVID-19. Nature 591, 92–98 (2021).

PubMed  Article  CAS  Google Scholar 

COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature 600, 472–477 (2021).

Article  CAS  Google Scholar 

Kalil, A. C. et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir. Med. 12, 1365–1376 (2021).

Article  Google Scholar 

Wilk, J. A. et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat. Med. 26, 1070–1076 (2020).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Wilk, A. J. et al. Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19. J. Exp. Med. 218, e20210582 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Reyes, M. et al. Induction of a regulatory myeloid program in bacterial sepsis and severe COVID-19. Preprint at bioRxiv https://doi.org/10.1101/2020.09.02.280180 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Falck-Jones, S. et al. Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity. J. Clin. Invest. 131, e144734 (2021).

CAS  PubMed Central  Article  Google Scholar 

Channappanavar, R. & Perlman, S. Age-related susceptibility to coronavirus infections: role of impaired and dysregulated host immunity. J. Clin. Invest. 130, 6204–6213 (2020).

PubMed  PubMed Central  Article  Google Scholar 

Wong, L. R. Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19. Nature 605, 146–151 (2022).

CAS  PubMed  Article  Google Scholar 

Gralinski, L. E. et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio 9, e01753-18 (2018).

PubMed  PubMed Central  Article  Google Scholar 

Sefik, E. et al. Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature 606, 585–593 (2022).

CAS  PubMed  Article  Google Scholar 

Wahl, A. et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 591, 451–457 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Karki, R. Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell 184, 149–168 (2021).

CAS  PubMed  Article  Google Scholar 

Liu, G. et al. ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity. Nat. Microbiol. 6, 467–478 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Pfaender, S. et al. LY6E impairs coronavirus fusion and confers immune control of viral disease. Nat. Microbiol. 5, 1330–1339 (2020).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Martin-Sancho, L. et al. Functional landscape of SARS-CoV-2 cellular restriction. Mol. Cell. 81, 2656–2668 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Severe Covid-19 GWAS Group. et al. Genomewide association study of severe Covid-19 with respiratory failure. N. Engl. J. Med. 383, 1522–1534 (2020).

Article  Google Scholar 

Schäfer, A. et al. A multitrait locus regulates sarbecovirus pathogenesis. Preprint at bioRxiv https://doi.org/10.1101/2022.06.01.494461 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Krämer, B. et al. Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity 54, 2650–2669 (2021).

PubMed  PubMed Central  Article  CAS  Google Scholar 

Winkler, E. S. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 21, 1327–1335 (2020).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Hoagland, D. A. et al. Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity. Immunity 54, 557–570 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370, eabd4570 (2020).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Liu, C. et al. Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19. Cell 184, 1836–1857 (2021).

CAS  PubMed  PubMed Central  Article  Google Scholar 

Abers, M. S. et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight 6, e144455 (2021).

PubMed Central  Article  Google Scholar 

Rovina, N. et al. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit. Care. 24, 187 (2020).

PubMed  PubMed Central  Article  Google Scholar 

Enocsson, H. Soluble urokinase plasminogen activator receptor (suPAR) independently predicts severity and length of hospitalisation in patients with COVID-19. Front. Med. https://doi.org/10.3389/fmed.2021.791716 (2021).